Breast Cancer 1, Early Onset Peptide 1


Background

Catalog Number:

CPTC-BRCA1-1

RRID:

AB_2617225

Target Antigen:

Breast Cancer 1, Early Onset Peptide 1

Isotype:

IgG1

Species:

Mouse Monoclonal Antibody

Last Updated:

03/25/2022

Antigen Recognition(s):

Peptide, Phosphorylation

Thematic Panel(s):

DNA Damage Response (DDR) Pathway

Purchase
Characterization Data [Compare Characterization Data]
  IP
Click to enlarge image Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-1 antibody with CPTC-BRCA1 peptide 1 (phosphorylated) as the target antigen. Click image to enlarge

CPTC-BRCA1-1 IPMS

Result: Positive

Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-1 antibody with CPTC-BRCA1 peptide 1 (phosphorylated) as the target antigen.


  IP
Click to enlarge image Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-1 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen. Click image to enlarge

CPTC-BRCA1-1 IPMS (non-phospho)

Result: Positive

Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-1 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen.


  Western Blot - Tissue or Cell Lysate
Click to enlarge image Western blot using CPTC-BRCA1-1 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-1 Western Blot

Result: Negative

Western blot using CPTC-BRCA1-1 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Characterization SOP Files

  Western Blot - Tissue or Cell Lysate
Click to enlarge image Automated western blot using CPTC-BRCA1-1 as primary antibody against against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-1 Automated Western Blot Cell Lysate

Result: Negative

Automated western blot using CPTC-BRCA1-1 as primary antibody against against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Background

Catalog Number:

CPTC-BRCA1-2

RRID:

AB_2722030

Target Antigen:

Breast Cancer 1, Early Onset Peptide 1

Isotype:

IgG1

Species:

Mouse Monoclonal Antibody

Last Updated:

03/25/2022

Antigen Recognition(s):

Peptide

Thematic Panel(s):

DNA Damage Response (DDR) Pathway

Purchase
Characterization Data [Compare Characterization Data]
  IP
Click to enlarge image Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-2 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen. Click image to enlarge

CPTC-BRCA1-1 IPMS non-phospho

Result: Positive

Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-2 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen.


  IP

CPTC-BRCA1-2 IPMS (phospho)

Result: Negative

CPTC-BRCA1-2 antibody did not react with phosphorylated BRCA1 peptide 1 using the IPMS procedure


  Western Blot - Tissue or Cell Lysate
Click to enlarge image Western blot using CPTC-BRCA1-2 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-2 Western Blot

Result: Negative

Western blot using CPTC-BRCA1-2 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Characterization SOP Files

  Western Blot - Tissue or Cell Lysate
Click to enlarge image Automated western blot using CPTC-BRCA1-2 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-2 Automated Western Blot Cell Lysate

Result: Negative

Automated western blot using CPTC-BRCA1-2 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Background

Catalog Number:

CPTC-BRCA1-3

Target Antigen:

Breast Cancer 1, Early Onset Peptide 1

Isotype:

IgG1

Species:

Mouse Monoclonal Antibody

Last Updated:

03/25/2022

Antigen Recognition(s):

Peptide, Phosphorylation

Thematic Panel(s):

DNA Damage Response (DDR) Pathway

Characterization Data [Compare Characterization Data]
  IP
Click to enlarge image Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-3 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen. Click image to enlarge

CPTC-BRCA1-3 IPMS non-phospho

Result: Positive

Immuno-Precipitation Mass Spectrometry using CPTC-BRCA1-3 antibody with CPTC-BRCA1 peptide 1 (non-phosphorylated) as the target antigen.


  IP

CPTC-BRCA1-3 IPMS (phospho)

Result: Negative

CPTC-BRCA1-3 antibody did not react with phosphorylated BRCA1 peptide 1 using the IPMS procedure


  Western Blot - Tissue or Cell Lysate
Click to enlarge image Western blot using CPTC-BRCA1-3 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-3 Western Blot

Result: Negative

Western blot using CPTC-BRCA1-3 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Characterization SOP Files

  Western Blot - Tissue or Cell Lysate
Click to enlarge image Automated western blot using CPTC-BRCA1-3 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-3 Automated Western Blot Cell Lysate

Result: Negative

Automated western blot using CPTC-BRCA1-3 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Background

Catalog Number:

CPTC-BRCA1-4

Target Antigen:

Breast Cancer 1, Early Onset Peptide 1

Isotype:

IgG

Species:

Rabbit Monoclonal Antibody

Last Updated:

02/02/2024

Antigen Recognition(s):

Peptide, Phosphorylation

Thematic Panel(s):

DNA Damage Response (DDR) Pathway

External Links
Purchase
Publications
Characterization Data [Compare Characterization Data]
  Immuno-MRM
Click to enlarge image Immuno-MRM chromatogram of CPTC-BRCA1-4 antibody (see CPTAC assay portal for details:  https://assays.cancer.gov/CPTAC-3219)

Data provided by the Paulovich Lab, Fred Hutch (https://research.fredhutch.org/paulovich/en.html) Click image to enlarge

CPTC-BRCA1-4 iMRM

Result: Positive

Immuno-MRM chromatogram of CPTC-BRCA1-4 antibody (see CPTAC assay portal for details: https://assays.cancer.gov/CPTAC-3219)

Data provided by the Paulovich Lab, Fred Hutch (https://research.fredhutch.org/paulovich/en.html)


  Western Blot - Tissue or Cell Lysate
Click to enlarge image Western blot using CPTC-BRCA1-4 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-4 Western Blot

Result: Negative

Western blot using CPTC-BRCA1-4 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Characterization SOP Files

  Western Blot - Tissue or Cell Lysate
Click to enlarge image Automated western blot using CPTC-BRCA1-4 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates.  Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa.  Molecular weight standards are also included (lane 1). Click image to enlarge

CPTC-BRCA1-4 Automated Western Blot Cell Lysate

Result: Negative

Automated western blot using CPTC-BRCA1-4 as primary antibody against HT-29 (lane 2), HeLa (lane 3), MCF7 (lane 4), HL-60 (lane 5), Hep G2 (lane 6), and MCF7 (lane 7) whole cell lysates. Expected molecular weight - 208 kDa, 7 kDa, 85 kDa, 206 kDa, 81 kDa, 78 kDa, 210 kDa, and 202 kDa. Molecular weight standards are also included (lane 1).


Background

NCI Identification Number:

00088

Antigen Name:

Breast Cancer 1, Early Onset Peptide 1

CPTC Name:

CPTC-BRCA1 Peptide 1

Aliases:

Breast Cancer 1, Early Onset; RNF53; RING Finger Protein 53; BROVCA1; PNCA4; PSCP; BRCA1/BRCA2-Containing Complex; Protein Phosphatase 1; Regulatory Subunit 53; Subunit 1; BRCAI; BRCC1; IRIS; PPP1R53; BRCA1/BRCA2-Containing Complex, Subunit 1; Breast And Ovarian Cancer Susceptibility Protein1; Breast Cancer Type 1 Susceptibility Protein; Protein Phosphatase 1, Regulatory Subunit 53; EC 6.3.2.

Function:

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.

BRCA1 (breast cancer 1, early onset) is a protein-coding gene. Diseases associated with BRCA1 include primary peritoneal carcinoma, and hereditary site-specific ovarian cancer syndrome. GO annotations related to this gene include RNA binding and enzyme binding.

E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to
mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8.

Chromosomal Localization:

17q21.32

Accession Number:

NP_009225.1

UniProt Accession Number:

P38398

DNA Source:

N/A

Immunogen:

Synthetic Peptide

Vector Name:

N/A

Extinction Coefficient:

Buffers:

Expressed Sequence:

NYP(pS)QEELIK

Native Sequence:

Calculated Isoelectric Point:

0

Molecular Weight:

1100

Last Updated:

09/01/2020

Links

Characterization Data

SOPs

No SOPs available.

Don't have Adobe Reader™?

Get it for free at Adobe.com